

PLENARY LECTURES

- 1) Gene editing: powerful new tool for nephrology research and therapy
Toni Cathomen, Freiburg, Germany
- 2) New paradigms of the kidney - Vascular-Bone axis in CKD
Klaus Olgaard, Copenhagen, Denmark
- 3) From the RNA world to the clinic: RNAs as drugs and drug targets
Bruce Sullenger, Durham, USA
- 4) Epidemiology of kidney disease
Marcello Tonelli, Calgary, Canada

MINI LECTURES

Oxygen sensing – from physiology to clinical application
Kai-Uwe Eckardt, Berlin, Germany

New ideas on the link between salt and hypertension
Friedrich C. Luft, Berlin, Germany

Current place of vaptans in the treatment of hyponatremia
Goce Spasovski, Skopje, F.Y.R. of Macedonia

MicroRNAs, mediators and therapeutic targets for renal disease
Laura Denby, Edinburgh, United Kingdom

Economics of ADPKD: cost-effectiveness of medical treatment?
Jonathan G. Fox, Glasgow, United Kingdom

Role of Wnt signaling in renal fibrosis
Speaker to be confirmed

The new standardized classification of glomerulonephritis
Sanjeev Sethi, Rochester, U.S.A.

Treatment of C3 glomerulopathy
Yasar Caliskan, Istanbul, Turkey

Treatment of complement related glomerulopathies including HUS
Giuseppe Remuzzi, Bergamo, Italy

Treatment of HCV in CKD/ESRD: challenges and opportunities
Michel Jadoul, Brussels, Belgium

Changing face of HIV related kidney disorders
Alberto Ortiz, Madrid, Spain

Liquid kidney biopsy
- Yes! We are there
Harald Mischak, Hannover, Germany
- No, at least by now
Kerstin Amann, Erlangen, Germany

The diagnosis of hematuria in the genetic era: a conundrum solved?
Emmanuelle Plaisier, Paris, France

ANCA-associated vasculitis: should it be split into (at least) two diseases?
Benjamin Terrier, Paris, France

Biomarkers in IgA nephropathy
Dita Maixnerova, Prague, Czech Republic

Frailty in CKD/ESRD
Dimitrios Goumenos, Patras, Greece

How to increase serum Klotho concentration?
Makoto Kuro-o, Shimotsuke, Japan

FGF23 as a predictor of cardiovascular outcomes in CKD
Martin De Borst, Groningen, The Netherlands

Gut-microbiota in immune-mediated inflammatory diseases
Loreto Gesualdo, Bari, Italy

Factors affecting adherence in CKD
Anna Birna Almarsdóttir, Copenhagen, Denmark

Challenges and opportunities in the conduct of clinical trials in nephrology
Adeera Levin, Vancouver, Canada

Inflammation as a driver of premature aging in CKD
Peter Stenvinkel, Stockholm, Sweden

Atrial fibrillation in ESRD - what is the best approach to treatment
Adrian Covic, Iasi, Romania

Milestones in hyperkalemia therapy or just an innovation
Ziad Massy, Paris, France

Aldosterone inhibition in ESRD patients
Patrick Rossignol, Vandoeuvre-Les-Nancy, France

Resistant hypertension in ESRD - is it just water that matters?
Francesca Mallamaci, Reggio Calabria, Italy

Implementation of new CKD-MBD guidelines
Markus Ketteler, Coburg, Germany

Neprilysin inhibition in heart failure and CKD - a double-edged sword?

Richard Haynes, Oxford, United Kingdom

Renal anemia of inflammation

Yalcin Solak, Sakarya, Turkey

What can the Danish Nephrology Registry teach us?

James Heaf, Roskilde, Denmark

Impact of transitioning between modalities: the INTEGRATED project

Wim Van Biesen, Ghent, Belgium

Clinical implications of peritoneal transport physiology

Olof Heimbürger, Stockholm, Sweden

New clinical trials on kidney transplantation

Josep Cruzado, Barcelona, Spain

Xenotransplantation - a realistic solution?

Speaker to be confirmed

Criteria to define transplantable kidneys

Giuseppe Grandaliano, Foggia, Italy

How do we treat diabetic patients in stage 4-5 CKD

Speaker to be confirmed

Bariatric surgery and kidney functions

Speaker to be confirmed

The presence and the future of antihypertensive therapy

Giuseppe Mancia, Milan, Italy

AKI in the patient with cirrhosis

Andrew Davenport, London, UK

Staging AKI: from RIFLE to KDIGO to Delta-creatinine?

Norbert H. Lameire, Ghent, Belgium

CI-AKI: are the contrast agents really harmful?

Jolanta Malyszko, Bialystok, Poland

Using digital and mobile tools in clinical research

Mitchell R. Lunn, San Francisco, USA

News in the antique concept of Morbus Dominorum: gout as disease of lords

Vincenzo Savica, Messina, Italy

in collaboration with the International Association for the History of Nephrology (IAHN)



SYMPOSIA

SPECIAL AND JOINT SYMPOSIA

Late breaking clinical trials

ERA-EDTA Registry

- Trends in the Kidney Donor Risk Index (KDRI) in Europe
Maria Pippias, Amsterdam, The Netherlands
- The European EDITH kidney patients survey on treatment modality choice
Rianne de Jong, Amsterdam, The Netherlands
- Nutritional status in advanced CKD (EQUAL)
Speaker to be confirmed
- European disparities in access to transplantation and graft failure in children
Marjolein Bonthuis, Amsterdam, The Netherlands



American Society of Nephrology (ASN) Highlights



ERA-EDTA and Japanese Society of Nephrology (JSN)

Acute/rapidly-progressive nephritic syndrome and vasculitis

- Japanese Renal Biopsy Registry (JRBR)
Hitoshi Sugiyama, Okayama, Japan
- A nation-wide prospective cohort study in Japanese patients with ANCA-associated vasculitis
Shinya Kaname, Tokyo, Japan
- Geographical difference – different incidence of glomerular disease or different practice
Loreto Gesualdo, Bari, Italy
- Complications after renal biopsy - what are the risk factors?
Bjorn Peters, Skövde, Sweden



ERA-EDTA and Chinese Society of Nephrology (CSN)



ERA-EDTA and European Society of Hypertension (ESH)



ERA-EDTA and European Society for Paediatric Nephrology (ESPN)



Track 1

FLUID & ELECTROLYTES, TUBULAR TRANSPORT, RENAL PHYSIOLOGY

Renal physiology - tubular transport

- Claudins in the distal nephron
Speaker to be confirmed
- Tubular handling of calcium and magnesium:
Insights from GWAS
Olivier Devuyst, Zürich, Switzerland
- HNF1beta: roles in the distal nephron
Stanislas Faguer, Toulouse, France

Mitochondria: critical players in kidney disorders

- Podocyte metabolism in health and disease
Tobias Huber, Hamburg, Germany
- Mitochondrial cytopathies and the kidney
Francesco Emma, Rome, Italy
- Mitochondrial dysfunction in AKI
Ariela Benigni, Bergamo, Italy

APOL1 impact in kidney disease

- Pathogenic roles of lipoproteins and apolipoproteins in kidney diseases
Arnold Von Eckardstein, Zürich, Switzerland
- The APOL1-associated spectrum of chronic kidney disease
Barry I. Freedman, Winston-Salem, U.S.A.
- A mouse model of APOL1-associated kidney disease
Speaker to be confirmed

Track 2

HEREDITARY DISORDERS, DEVELOPMENT, PREGNANCY, PAEDIATRIC NEPHROLOGY

Recent findings in ADPKD

- Utility of prognostic scores in ADPKD
Emilie Cornec-Le Gall, Brest, France
- Low-osmolar diet and adjusted water intake in ADPKD
Albert Ong, Sheffield, United Kingdom
- New genes for cystic kidneys and liver
Peter Harris, Rochester, U.S.A.
- Use of urine peptidome analysis in ADPKD
Giovambattista Capasso, Naples, Italy

Paediatric nephrology

- Long-term outcome of patients with Lowe syndrome and Dent disease 2
Detlef Bockenhauer, London, United Kingdom
- Primary disease recurrence - effects on paediatric renal transplantation outcomes
Speaker to be confirmed
- Methylmalonic aciduria (MMA): new therapeutic perspectives
Speaker to be confirmed
- Minimal Change Disease
Marina Vivarelli, Rome, Italy

Pregnancy, CKD and hypertension

- The role of antihypertensive treatment in pregnant women with diabetic nephropathy
Elisabeth R. Mathiesen, Copenhagen, Denmark
- The role of home blood pressure measurements in pregnancy complicated by hypertension
Marianne Vestgaard, Copenhagen, Denmark
- Preconception cardiovascular risk factors for gestational hypertension and preeclampsia
Speaker to be confirmed
- Preeclampsia - does it predict kidney and cardiovascular disease in the future
Speaker to be confirmed
- Complement activation in kidneys; more than just a signature of IgG deposition
Cees Van Kooten, Leiden, The Netherlands



Track 3

GLOMERULAR DISEASES AND GENERAL CLINICAL NEPHROLOGY

Membranous nephropathy: the evolving story

- Advances in the pathogenesis of membranous nephropathy
Pierre Ronco, Paris, France
- Membranous nephropathy and cancer
Rolf A.K. Stahl, Hamburg, Germany
- New perspectives from recent treatment trials in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands

IgA nephropathy: from genes to therapeutic controversies

- From genetics to pathophysiology
Jan Novak, Birmingham, U.S.A.
- Towards pathology-based therapy? Towards a personalized therapy in IgAN
Rosanna Coppo, Turin, Italy
- From experimental models to new treatment options in humans
Renato Monteiro, Paris, France
- New and next therapeutic approaches
Jürgen Floege, Aachen, Germany

Plasma cell dyscrasias and the kidney

- Myeloma cast nephropathy - any role for extracorporeal treatments?
Frank Bridoux, Poitiers, France
- Primary amyloidosis - current best practices
Romana Rysava, Prague, Czech Republic
- Randall-type monoclonal immunoglobulin deposition disease
Camille Cohen, Paris, France
- MGUS and glomerulonephritis - how to find a causal relationship and how to treat
Sanjeev Sethi, Rochester, U.S.A.

Rituximab in immune mediated glomerular diseases: one drug does not fit all

- Anti-B cell targeted therapy: anti CD20 and other approaches
Annette Bruchfeld, Stockholm, Sweden
- Rituximab in idiopathic membranous nephropathy
Pierre Ronco, Paris, France
- Rituximab in IgA nephropathy
Fernando Fervenza, Rochester, USA
- Rituximab in ANCA vasculitis
David Jayne, Cambridge, United Kingdom

Lupus and vasculitis - recent advances in therapy

- Newer agents in the treatment of SLE nephritis
David Jayne, Cambridge, United Kingdom
- Anti-GBM disease - New subgroups and novel therapies
Mårten Segelmark, Linköping, Sweden



- IgA Vasculitis in adults: what is it and what should we do about it?

Alan D. Salama, London, United Kingdom

- Improving survival in ANCA associated vasculitis

Wladimir M. Szpirt, Copenhagen, Denmark

Glomerular diseases in the Omics era

- Large-scale genomic studies: what they have taught us
Alexander Teumer, Greifswald, Germany
- An integrated view of glomerular pathology
Tobias Huber, Hamburg, Germany
- Transcontinental Omics studies
Xueqing Yu, Guangzhou, P.R. China
- Integrative omics approach for comprehensive IgA nephropathy
Francesco Paolo Schena, Bari, Italy

Track 4

CKD - PATHOPHYSIOLOGY, EPIDEMIOLOGY, PREVENTION, PROGRESSION, AGEING

Update in plasmapheresis for treating kidney diseases

- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome
Petar Kes, Zagreb, Croatia
- Renal transplantation
Paolo Malvezzi, Grenoble, France
- Anti-neutrophil cytoplasm antibodies-associated vasculitis
Charles Pusey, London, United Kingdom
- FSGS - soluble or solid?
Mario Schiffer, Hannover, Germany

Progression of chronic kidney disease - hot issues beyond blood pressure and renin-angiotensin system

- Can antidiabetic drugs prevent chronic kidney disease progression?
Christoph Wanner, Würzburg, Germany
- Interventional antihypertensive therapies and chronic kidney disease - a new window of opportunity?
Johannes F.E. Mann, Munich, Germany
- Does metabolic acidosis correction prevent chronic kidney disease progression?
Marcin Adamczak, Katowice, Poland
- Hyperuricemia and chronic kidney disease progression
Ivan Rychlik, Prague, Czech Republic

New biomarkers of CKD progressions

- A new role for suPAR?
Jack F.M. Wetzels, Nijmegen, The Netherlands
- Phosphate toxicity and CKD progression
Markus Ketteler, Coburg, Germany
- Clinical consequences of hypervolemia in CKD patients
Andrzej J. Wiecek, Katowice, Poland
- Klotho and endocrine FGFs – marker of CKD progression and cardiovascular complications?
Makoto Kuro-o, Shimotsuke, Japan

Interstitial fibrosis and mechanisms of CKD progression

- New concepts in the pathogenesis of interstitial fibrosis
Peter Boor, Aachen, Germany
- Are there early biomarkers of interstitial fibrosis?
Christos Chatziantoniou, Paris, France
- The role of hypoxia in the progression of polycystic kidney disease
Kai-Uwe Eckardt, Berlin, Germany
- Interstitial fibrosis in kidney transplant recipients
Marian Klinger, Wroclaw, Poland

Controversy: too much Nephrology?

- The CKD epidemics is overstated
- The CKD epidemics is real and concerning

Focus on surrogate end-points in Nephrology

- Clinical end-points in Nephrology: less simple than it may seem
Kitty J. Jager, Amsterdam, The Netherlands
- Proteinuria as a clinical end-point in clinical trials in Nephrology: acceptable but not perfect
Ron T. Gansevoort, Groningen, The Netherlands
- Coronary calcification as a cardiovascular end-point in clinical trials in nephrology: lights and shades
Gérard London, Fleury-Mérogis, France

CKD as a public health priority: organizational models

- CKD Epidemiology in 2017-2050: primary and secondary prevention
Marcello Tonelli, Calgary, Canada
- Individualised care for kidney disease without hospital-based clinics?
Charles Tomson, Bristol, United Kingdom
- Integrated clinical care for CKD
Adeera Levin, Vancouver, Canada

n-3 PUFA in CKD: does it matter?

- n-3 PUFA and CKD: epidemiological data and follow-up
Anupam Chandra, Oslo, Norway
- Arrhythmias and sudden cardiac death in dialysis patients: is n-3 PUFA of relevance?
Jesper Moesgaard Rantanen, Aalborg, Denmark
- n-3 PUFA, inflammation and fibrosis. New insights
Ivar Anders Eide, Lørenskog, Norway
- n-3 PUFA and interventional studies relevant for the nephrologist
My Svensson, Lørenskog, Norway



CKD - new therapeutic approaches

- New treatments in diabetic kidney disease
Peter Rossing, Gentofte, Denmark
- Blood pressure regulation in CKD stage 1-5 (non-dialysis). Achievement of treatment goals and adherence to treatment
Niels Henrik Buus, Aarhus, Denmark



- Multifactorial risk reduction in CKD - with or without diabetes
Rikke Borg, Roskilde, Denmark
- The New Nordic Renal Diet
Louise Salomo, Copenhagen, Denmark

Track 5

END-STAGE RENAL DISEASE, HAEMODIALYSIS

Scheduling dialysis and hemodiafiltration in 2018: a new portfolio?

- Daily and frequent dialysis schedules: rationale, logistics and outcomes
Nicholas Selby, Derby, United Kingdom
- Incremental dialysis
Andrew Davenport, London, United Kingdom
- High convective volume in hemodiafiltration: an open question
Francesco Locatelli, Lecco, Italy

The non-dialysis pathway in ESRD

- Palliative care in ESRD: an overview
Aine Burns, London, UK
- End-of-life perspectives in haemodialysis
Stefan H. Jacobson, Stockholm, Sweden
- The non-dialysis pathway: models of care
Elizabeth Krarup, Herlev, Denmark
- Patient-reported outcome measures in ESRD: relevance for renal palliative care
Karl-Göran Prütz, Helsingborg, Sweden



Uremic toxicity - New insights

- Uremic toxins and the gut
Griet Glorieux, Ghent, Belgium
- Uremic toxins and cardiovascular outcomes
Ziad Massy, Paris, France
- Uremic toxins and the bone in CKD
Tilman Drueke, Villejuif, France
- Role of inflammation in the uremic phenotype
Peter Stenvinkel, Stockholm, Sweden

New methods of anaemia management in CKD patients

- PHIs - safety and efficacy - results from recent clinical trials
David Wheeler, London, United Kingdom
- Iron supplementation in CKD patients – what is the optimal dose and route of administration in 2018?
Iain C. Macdougall, London, United Kingdom
- Mechanisms of hypertension induced by erythropoietin and related agents
Speaker to be confirmed
- What is the future of rHuEPO?
Francesco Locatelli, Lecco, Italy

Neurologic disturbances in CKD

- Acute and chronic cognitive changes in CKD
David Goldsmith, London, United Kingdom
- Sleep disturbances in ESRD
Claire Kennedy, Dublin, Ireland
- Headaches during haemodialysis - headaches and treatment
Speaker to be confirmed

Cardiovascular calcifications in CKD

- Pathophysiology of vascular calcification
Mario Cozzolino, Milan, Italy
- Vitamin K in CKD patients
Jürgen Floege, Aachen, Germany
- Calcium sensing receptors
Jordi Bover, Barcelona, Spain
- Energy-dense diets and vascular calcification
J. Mariano Rodriguez Portillo, Cordoba, Spain

Treatment of CKD-MBD

- Are all phosphate binders the same for CKD patients?
João M. Frazão, Porto, Portugal
- Calcimimetics or vitamin D derivatives in ESRD patients?
John Cunningham, London, United Kingdom
- Osteoporosis in patients with CKD
Marie-Hélène Lafage-Proust, St. Etienne, France
- Treatment and prevention of fractures in kidney graft recipients
Rudolf Wüthrich, Zürich, Switzerland

The diagnosis of Heart Failure in End Stage Kidney Disease (ESKD): a lingering dilemma

- Diagnosis, classification and staging in Medicine: methodology issues
Speaker to be confirmed
- Acute and chronic heart-kidney interactions
Claudio Ronco, Vicenza, Italy
- Can the ESC guidelines for diagnosis of heart failure be applied among CKD patients?
Vincent Brandenburg, Aachen, Germany

DOPPS - The sweet truth: Optimizing care in advanced CKD and dialysis with a focus on diabetic patients



- DOPPS Program: The burden of diabetes in advanced CKD and dialysis
Bruce Robinson, Ann Arbor, USA
- PDOPPS: Variation in the PD prescription, glucose exposure and outcomes
Mark Lambie, Stoke-On-Trent, United Kingdom
- DOPPS: Hepatitis C in HD patients - prevalence trends over 20 years, outcomes and use of newer treatments
Michel Jadoul, Brussels, Belgium
- CKDopps: Diabetes treatment, control and hypoglycemia in patients with advanced CKD
Bénédicte Stengel, Villejuif, France

- EURODOPPS: Outcomes according to different strategies of HbA1c use among diabetic HD patients
Ionut Nistor, Iasi, Romania

Track 6

HOME THERAPIES, PERITONEAL DIALYSIS

Lessons from International Databases

In collaboration with

the International Society for Peritoneal Dialysis (ISPD)



- SONG-PD
Karine Manera, Sydney, Australia
- Achieving optimal catheter function. Early insights from PDOPPS and UK-Catheter Study
Martin Wilkie, Sheffield, United Kingdom
- An update from the IPDN (International Paediatric Dialysis Network)
Franz Schaefer, Heidelberg, Germany

Optimising clinical outcomes and technique survival

- How to reduce technique failure due to peritonitis - the ANZDATA experience
Speaker to be confirmed
- The role of training in peritonitis prevention - what we have learned from the PEPS Study (Prevention of Peritonitis in Peritoneal Dialysis)
Susanne Ljungman, Gothenburg, Sweden
- What is the role of assisted PD in the outcomes of frail elderly patients?
Edwina Brown, London, United Kingdom

Optimising fluid management in PD patients

- Bioimpedance: what have we learned from the IPOD-PD Study
Wim van Biesen, Ghent, Belgium
- Managing blood pressure in PD patients: what is the optimal balance between bioimpedance directed volume status, salt restriction, pharmacological management and sodium removal?
Olof Heimbürger, Stockholm, Sweden
- What is the role of low sodium solutions?
Speaker to be confirmed

Home haemodialysis in Europe 2018

- What to do for more frequent use of home haemodialysis in Europe
Speaker to be confirmed
- Home haemodialysis and control of phosphatemia
Antonio Bellasi, Milan, Italy
- Home haemodialysis and quality of life
Edwina Brown, London, United Kingdom

Track 7

TRANSPLANTATION AND IMMUNOLOGY

Hot and new in transplantation: selected topics from 2017/18

- Relevant outcomes? The SONG Initiative (Standardized Outcomes In Nephrology)
Lionel Rostaing, Grenoble, France
- Steroid withdrawal: if and when?
Maria Haller, Linz, Austria
- Do we still need calcineurin inhibitors in 2018?
Daniel Abramowicz, Antwerp, Belgium
- Dialysis vintage and outcomes
Rainer Oberbauer, Vienna, Austria

Humoral immunity (HLA and nonHLA)

- Allorecognition revisited
Frans H.J. Claas, Leiden, The Netherlands
- Histopathology of humoral alloimmunity
Jan Becker, Cologne, Germany
- Anti-HLA antibodies - consequences and intervention
Speaker to be confirmed
- Sensitization to non-HLA epitopes - is this clinical relevant?
Georg Böhmig, Vienna, Austria

Expanding the donor pool (deceased and live donors) KPD, ABOi, machine perfusion

- How to set up a KPD Program
Ondrej Viklicky, Prague, Czech Republic
- ABO-I and HLA-I transplantation
Umberto Maggiore, Parma, Italy
- DCD - Programs
Speaker to be confirmed
- Marginal kidney donors
Johan W. De Fijter, Leiden, The Netherlands

Post transplantation diabetes mellitus - relation to obesity and new options/challenges

- Peripheral or central resistance-pre and post transplant factors in PTDM
Morten Buus Jørgensen, Copenhagen, Denmark
- Insulin secretion and immunosuppression related pathogenesis of PTDM
Trond Jenssen, Oslo, Norway
- New gastrointestinal hormones for glucose control in obesity and type 2 diabetes - any role in diabetes after transplantation?
Tina Vilsbøll, Copenhagen, Denmark
- Clinical evolution of PTDM
Esteban Porrini, La Laguna, Spain



Risk profiling in renal transplant patients

- Metabolic risk profile in renal transplant candidates and in renal transplant patients
Umberto Maggiore, Parma, Italy
- CV risk in potential renal transplant recipients
Alan Jardine, Glasgow, UK
- Nocturnal hypertension and renal function loss in renal transplant patients
George Reusz, Budapest, Hungary

Track 8

HYPERTENSION, DIABETES, VASCULAR DISEASES

Hot topics in hypertension

- Early vascular aging, hypertension and cardiovascular disease
Stéphane Laurent, Paris, France
- Looking for optimal target blood pressure: implications of the recent trials
Sverre E. Kjeldsen, Oslo, Norway
- Measuring, analyzing and managing drug adherence
Michel Burnier, Lausanne, Switzerland
- Potential new targets for antihypertensive therapy
Krzysztof Narkiewicz, Gdansk, Poland

A new life for sodium in Nephrology

- Sodium and ADPKD progression
Vicente Torres, Rochester, U.S.A.
- Sodium and the evolution of CKD
Gerjan Navis, Groningen, The Netherlands
- Proteasuria – the primary mechanism for sodium retention in proteinuric kidney disease
Ferruh Artunc, Tübingen, Germany

Diabetic nephropathy

- Urine proteome - is there a role in predicting and monitoring diabetic nephropathy
Peter Rossing, Gentofte, Denmark
- SGLT2 inhibitors, mechanisms behind cardiovascular and renal protection?
Bo Feldt-Rasmussen, Copenhagen, Denmark
- Incretin based therapies, mechanisms behind cardiovascular and renal protection?
Johannes F.E. Mann, Munich, Germany
- Ongoing studies in the field
Speaker to be confirmed



Track 9

ACUTE KIDNEY INJURY AND INTENSIVE CARE NEPHROLOGY

AKI biomarkers and risk factors

- Novel biomarkers for prediction/detection of AKI
Danilo Fliser, Homburg/Saar, Germany
- Leukocyte integrin CD11b/CD18
Speaker to be confirmed
- NETs and histones, new players in AKI and AKI-related remote organ injury
Hans-Joachim Anders, Munich, Germany
- Biomarkers for early detection and prognosis of AKI
Raymond Vanholder, Ghent, Belgium

AKI in various circumstances

- AKI in the intensive care unit
Michael Joannidis, Innsbruck, Austria
- AKI after kidney transplantation
Alexandre Hertig, Paris, France
- AKI during disasters
Mehmet Sukru Sever, Istanbul, Turkey
- Consulting the patient with AKI in other clinics: what should be stressed by the nephrologist?
Mustafa Arici, Ankara, Turkey

Renal Replacement Therapy in the Intensive Care Unit

- Renal replacement therapy indications in patients with severe AKI in ICU
Julien Maizel, Amiens, France
- Continuous Renal Replacement Therapy
Esteban Poch López de Briñas, Spain
- Pro RRT Delayed strategy
Stéphane Gaudry, Colombes, France
- Con RRT Delayed strategy
Melanie Meersch, Münster, Germany

SPECIAL SESSION

Nephrology Pearls

CME COURSES

IWG -

Immunonephrology Working Group News in the pathogenesis and treatment of immune-mediated renal diseases



Part 1

Cyclophosphamide in glomerular disease: is this old drug still to be used or does it have to be dismissed?

- Introduction and the case of ANCA-associated vasculitis
Yasar Caliskan, Istanbul, Turkey
- The case of lupus nephritis
Vladimir Tesar, Prague, Czech Republic
- The case of membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
- Minimal change disease - Focal glomerulosclerosis
Claudio Ponticelli, Milan, Italy

Part 2

Renal involvement in rare inflammatory diseases

- IgG4-related renal disease
Giacomo Quattrocchio, Turin, Italy
- Inflammation in crystal nephropathies
Hans-Joachim Anders, Munich, Germany
- Renal involvement in Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Speaker to be confirmed
- Renal involvement in scleroderma
Speaker to be confirmed



(EURECA-m Working Group - European Renal and Cardiovascular Medicine) The challenge of decreasing cardiovascular mortality in CKD

Part 1

New therapeutic approaches to improve cardiovascular outcomes in CKD patients

- Challenges and opportunities of potassium management in CKD and hypertension
Patrick Rossignol, Vandoeuvre-Les-Nancy, France
- Cardio- and nephroprotective properties of SGLT-2 inhibitors: mechanisms and future potential
Pantelis A. Sarafidis, Thessaloniki, Greece
- Iron supplementation in kidney and heart crosstalk: a hope for heart failure treatment
Mehmet Kanbay, Istanbul, Turkey

Part 2

Focus on prevention: health economy, blood pressure targets and choice of anticoagulation

- The health-economy of CKD: a plea for more prevention
Raymond Vanholder, Ghent, Belgium
- Hypertension metrics and treatment targets in renal transplantation: an update
Francesca Mallamaci, Reggio Calabria, Italy
- Anticoagulation in CKD patients with atrial fibrillation
Gunnar Heine, Homburg/Saar, Germany

**DESCARTES Working Group
(Developing Education Science and
Care for Renal Transplantation in
European States) in collaboration with
EKITA, the Organ Expert Section of ESOT
on kidney transplantation: what are the challenges
and opportunities ahead?**



- The European paired exchange program
Rainer Oberbauer, Vienna, Austria
- Machine perfusion: does it help to improve outcomes?
Gabriel C. Oniscu, Edinburgh, United Kingdom
- Minimisation strategies in kidney transplantation:
are we making progresses?
Ondrej Viklicky, Prague, Czech Republic
- FSGS in children
Licia Peruzzi, Turin, Italy
- The upcoming immunosuppressive drugs
Klemens Budde, Berlin, Germany
- Donor specific antibodies before and after
transplantation
Marta Crespo, Barcelona, Spain
- The future of kidney allocation within Eurotransplant
Uwe Heemann, Munich, Germany

**EUDIAL Working Group -
European Dialysis
Improving outcomes for the haemodialysis patient**



Part 1
Targets of treatment in dialysis patients

- Does achievement of solute clearance targets improve
patient outcomes
Andrew Davenport, London, United Kingdom
- Does achievement of blood pressure targets improve
patient outcomes
- Patient perspective of dialysis

Part 2

How to reduce cardiovascular risk?

- Detection, prevention and management of cardiac
arrhythmias during dialysis
- Atrial fibrillation: rate or rhythm control, anticoagulation:
yes or no
- Does bioimpedance and lung ultrasound guided
assessment of target weight improve outcomes
Carlo Basile, Acquaviva delle Fonti, Italy

ERA-EDTA Registry



- Modeling longitudinal data in survival analysis
- Interaction analyses
- How to validate the predictive value of a biomarker
- Grading evidence
- Impact of epidemiology on public health

European Renal Best Practice



**DIABESITY - Working Group
researching on the nephrological
impact in relation to diabetes and obesity
Insulin resistance and renal disease**



- Insulin resistance: pathogenesis and definitions
Drazenka Pongrac Barlovic, Ljubljana, Slovenia
- Muscle or liver?
Morten Buus Jørgensen, Copenhagen, Denmark
- Insulin resistance: cause or consequence of renal
disease?
Mads Hornum, Copenhagen, Denmark
- CKD, dialysis and insulin resistance
Danilo Fliser, Homburg/Saar, Germany
- Uremia, insulin resistance and beta-cell damage
Laetitia Koppe, Lyon, France
- Prediabetes and insulin resistance in the waiting list for
renal transplantation
Armando Torres, La Laguna (Tenerife), Spain

**Electrolytes and acid-base balance:
from physiology to clinic**

- Hypokalemia: a clinical perspective
- Hyponatremia and water balance disorders
Ewoot Hoorn, Rotterdam, The Netherlands
- Seeing the sodium in the patient
Christoph Kopp, Erlangen, Germany
- Mechanism and regulation of renal magnesium transport:
clinical implications
- New paradigms in renal phosphate handling
Carsten Wagner, Zurich, Switzerland
- Distal tubular acidosis: new findings
Francesco Trepiccione, Naples, Italy
- Key note talk: The effect of salt on the gut microbiome

**EUTox Working Group -
European Uremic Toxin**



**Uremic toxins: sources and alterations leading to
the uremic state**

- Systems medicine, molecular mechanisms and
pathways involved in CKD
Harald Mischak, Hannover, Germany
- Molecular modifications of proteins and peptides in CKD
Joachim Jankowski, Aachen, Germany
- MicroRNA and CKD
Laurent Metzinger, Amiens, France
- Sulfur amino acid metabolism derangement in uremia
Alessandra Perna, Naples, Italy
- Understanding the gut-kidney axis in chronic kidney
disease
Rosalinde Masereeuw, Utrecht, The Netherlands
- Uremic toxins and the gut microbiota
Griet Glorieux, Ghent, Belgium

EuroPD



**Integrating dialysis care: getting the best from
home therapies**

- How do we best help patients make an informed
modality choice?
Hillary Bekker, Leeds, United Kingdom
- What is the best way to deliver assisted peritoneal dialysis?
Thierry Lobbedez, Caen, France

- How can we best deliver an integrated home therapies dialysis programme?

James Heaf, Roskilde, Denmark

- Preventing technique failure in PD - what does it mean for the small dialysis programme?
Speaker to be confirmed

Vascular Access Society (VAS) in collaboration with the Young Nephrologists' Platform (YNP)



CKB-MBD Working Group Emerging insights in CKD-MBD



- Position of gastrointestinal sodium-phosphate transporter inhibition
Ziad Massy, Paris, France
- Novel approaches to treat renal osteodystrophy
João M. Frazão, Porto, Portugal
- CKD-MBD phenotypes and all-cause mortality
Marc Vervloet, Amsterdam, The Netherlands
- Novel compounds to regress ectopic calcification
Mario Cozzolino, Milan, Italy
- Ten years research on FGF23: will it ever enter clinical practice?
Sandro Mazzaferro, Rome, Italy
- Treatment of CKD-MBD after renal transplantation
Pieter Evenepoel, Leuven, Belgium

WGIKD - Working Group on Inherited Kidney Diseases What's new in rare kidney diseases?



- Ascertaining pathogenicity of genetic variants in congenital and inherited kidney disorders
Nine Knoers, Utrecht, The Netherlands
- Claudinopathies: a new class of tubulopathies
Dominik Müller, Berlin, Germany
- Diagnostic and therapeutic management of hypophosphatemic rickets from infancy to adulthood
Dominique Prié, Paris, France
- Novel therapeutic approaches in primary hyperoxaluria
Bernd Hoppe, Bonn, Germany
- What's new in Tuberous Sclerosis Complex?
Roser Torra, Barcelona, Spain
- Insights from urinary exosome analysis in inherited kidney diseases
Kirsten Y. Renkema, Utrecht, The Netherlands
- Transitioning rare kidney disease patients from paediatric to adult care
Speaker to be confirmed

Rheumatology for nephrologists

- Visual diagnosis quiz
Peter Herzer, Munich, Germany
- Back from the future - steroid free lupus therapy?
Speaker to be confirmed
- The conundrum of treating gout in patients with CKD
Jakub Závada, Prague, Czech Republic
- Forms of tubulointerstitial nephritis that need a rheumatology consult
Manuel Praga, Madrid, Spain

- Bortezomib and bone marrow transplantation - rescue options for severe SLE
Falk Hiepe, Berlin, Germany
- Can we ever stop immunosuppressive drugs in patients with systemic autoimmune diseases?
David Jayne, Cambridge, United Kingdom

Onconephrology

Part 1

- CKD in malignancy cause or consequence
Speaker to be confirmed
- Nephrologic management of renal and urothelial cancer
Speaker to be confirmed
- Kidney involvement in leukemia and lymphoma
Jan Kielstein, Braunschweig, Germany
- How to use wisely renal replacement therapy in oncology patients
Ben Sprangers, Leuven, Belgium

Part 2

- Hypertension in malignancy - comorbidity or complication of the therapy
Jolanta Malyszko, Bialystok, Poland
- Anemia in cancer patients to use or to avoid ESA and iron
Petra Tesarova, Prague, Czech Republic
- Acid base disturbances in cancer patients
Giovambattista Capasso, Naples, Italy
- Electrolytes disorders - common but underappreciated problem in malignancy and its treatment
Speaker to be confirmed

ERN Working Group - European Renal Nutrition Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD



- Introduction, overview and rationale for the guidelines
T. Alp Ikizler, Nashville, U.S.A.
- Methodology and development of the clinical evidence library
Deepa Handu, Chicago, U.S.A.
- Guideline recommendations for macronutrients
Denis Fouque, Lyon, France
- Guideline recommendations for micronutrients
Daniel Teta, Sion, Switzerland
- Guideline recommendations for electrolytes and other nutrients
Juan Jesus Carrero, Stockholm, Sweden

EULIS, the Section of Urolithiasis of the European Association of Urology



Ethical aspects in dialysis and kidney transplantation in the elderly

- Dialysis - Pro
- Dialysis - Con
- Kidney transplantation - Pro
- Kidney transplantation - Con

